Stock TZAC REVIVA PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Biotechnology & Medical Research

Business Summary

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Number of employees: 15

Managers

Managers TitleAgeSince
Laxminarayan Bhat FOU
 Founder 59 10/12/20
Narayan Prabhu DFI
 Director of Finance/CFO 53 13/12/20

Members of the board

Members of the board TitleAgeSince
Parag Phoolchand Saxena CHM
 Chairman 69 13/12/20
Les Funtleyder BRD
 Director/Board Member 54 13/12/20
Laxminarayan Bhat FOU
 Founder 59 10/12/20
Purav Patel BRD
 Director/Board Member 42 13/12/20
Richard Margolin BRD
 Director/Board Member 73 13/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,817,294 22,973,725 ( 77.05 %) 0 77.05 %

Shareholders

NameEquities%Valuation
Laxminarayan Bhat
8.898 %
2,484,244 8.898 % 7 M $
Vedanta Capital LLC
8.241 %
2,300,876 8.241 % 7 M $
Woodline Partners LP
3.779 %
1,055,009 3.779 % 3 M $
Vanguard Global Advisers LLC
3.588 %
1,001,836 3.588 % 3 M $
Millennium Management LLC
3.061 %
854,597 3.061 % 3 M $
Schonfeld Strategic Advisors LLC
2.961 %
826,600 2.961 % 2 M $
Parkman Healthcare Partners LLC
1.805 %
503,854 1.805 % 2 M $
Susquehanna Securities LLC
0.8692 %
242,667 0.8692 % 723 148 $
Geode Capital Management LLC
0.7884 %
220,117 0.7884 % 655 949 $
The Colony Group LLC
0.6125 %
171,000 0.6125 % 509 580 $
NameEquities%Valuation
Arena Investors LP
-
85,000 - 40 375 $
Walleye Capital LLC
-
33,718 - 16 016 $
Walleye Trading LLC
-
25,727 - 12 220 $
B. Riley Wealth Advisors, Inc.
-
11,101 - 5 273 $
UBS Securities LLC
-
10,481 - 4 978 $

Company contact information

Reviva Pharmaceuticals Holdings, Inc.

10080 North Wolfe Road Suite SW3-200

95014, Cupertino

+

http://www.revivapharma.com
address Reviva Pharmaceuticals Holdings, Inc.(TZAC)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RVPH Stock
  4. TZAC Stock
  5. Company Reviva Pharmaceuticals Holdings, Inc.